You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

HER2-low in Unresectable and/or Metastatic Breast Cancer

Not yet recruiting
  • Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
    • (no location specified)
    Nov 6, 2023

    18F-HER2 PET Trial in Hangzhou (18F-HER2 PET)

    Not yet recruiting
    • 18F-HER2 PET
    • 18F-HER2 PET
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, Zhejiang University School of med
    Aug 2, 2023

    HER2-low in Metastatic Breast Cancer Patients

    Not yet recruiting
    • HER2-negative
      • (no location specified)
      Nov 9, 2023

      HER2 Expression and Clinical Pathological Characteristics in

      Recruiting
      • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
      • Collect HER2 expression in prostate cancer patients
      • Jinan, Shandong, China
        Qilu hospital
      Nov 17, 2023

      HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

      Not yet recruiting
      • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
      • SHR-A1811
      • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
      • (no location specified)
      Nov 6, 2023

      HER2-positive Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      HER2-low Advanced Breast Cancer Patients Treated With ADC

      Recruiting
      • Breast Cancer
      • HER2 expression of circulating tumor cells
      • Beijing, Beijing, China
        The Fifth Medical Center of PLA General Hospital
      Apr 18, 2023

      Breast Cancer Trial (Trastuzumab Deruxtecan)

      Not yet recruiting
      • Breast Cancer
      • Trastuzumab Deruxtecan
      • (no location specified)
      Jul 10, 2023

      Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

      Not yet recruiting
      • Solid Tumor
      • Intravenous infusion anti-HER2-CAR-T cell
      • Shenyang, Liaoning, China
        Phase I Clinical Trials Center Of The First Hospital of China Me
      Oct 30, 2023

      HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

      Not yet recruiting
      • HER2 Positive Advanced Solid Tumors
      • HypoSti.CAR-HER2 T cells
      • +2 more
      • (no location specified)
      Jan 12, 2023

      Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Cessation of anti-HER2 treatment
      • Boston, Massachusetts
      • +1 more
      Feb 9, 2023

      HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance

      Recruiting
      • HER2-positive Metastatic Breast Cancer
      • Stage IV Breast Cancer
      • Discontinuation of Anti-HER-2 Maintenance Treatment
      • Miami, Florida
        University of Miami
      Jul 17, 2023

      DESTINY Breast Respond HER2-low Europe

      Not yet recruiting
      • Unresectable Breast Cancer
      • +2 more
      • Trastuzumab deruxtecan
      • (no location specified)
      Jul 6, 2023

      Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

      Active, not recruiting
      • Hormone-receptor-positive Breast Cancer
      • +2 more
      • No drug
      • Cambridge, Massachusetts
        ConcertAI database
      Sep 8, 2023

      HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Standard of Care Adjuvant Breast Radiation
      • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
      • (no location specified)
      Jan 20, 2023

      HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

      Recruiting
      • HER2-positive Gastric Cancer
      • Immunotherapy
      • Disitamab Vedotin combined with fruquintinib and Tislelizumab
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 8, 2023

      HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Colorectal Cancer
      • HER2-positive Biliary Tract Cancer
      • Beijing, State*, China
        Peking University cancer hospital & institution
      Aug 2, 2023

      Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

      Not yet recruiting
      • Breast Cancer Female
      • Pyrotinib and Trastuzumab
      • (no location specified)
      Sep 11, 2023

      HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

      Not yet recruiting
      • HER2 Low Breast Carcinoma
      • SHR-A1811 for injection
      • (no location specified)
      Jun 12, 2023

      Survival Rate of HER2-Low Breast Cancer Patients

      Completed
      • HER2 Low Breast Carcinoma
      • immunohistochemistry (IHC) and in situ hybridization (ISH) Test
      • (no location specified)
      Mar 2, 2023

      Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

      Recruiting
      • HER2-positive Breast Cancer
      • Early-stage Breast Cancer
      • pyrotinib combined with Capecitabine
      • treatment of physician's choice
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 6, 2023

      HER2-positive Locally Advanced Resectable Gastric Cancer Trial (KN026, KN046, XELOX)

      Not yet recruiting
      • HER2-positive Locally Advanced Resectable Gastric Cancer
      • (no location specified)
      Sep 3, 2023

      Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)

      Recruiting
      • Gastric Cancer
      • HER2-low-expressing Gastric Cancer
      • Shanghai, China
        Shanghai East Hospital
      Oct 9, 2023

      HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

      Not yet recruiting
      • HER2-positive Breast Cancer
      • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
      • (no location specified)
      Jul 20, 2023